XML 240 R163.htm IDEA: XBRL DOCUMENT v3.26.1
Equity-settled share-based transactions - Fair value valuation assumption, stock options, ACT Genomics (Details) - ACT genomics
12 Months Ended
Dec. 31, 2024
yr
$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Fair value at measurement date (in USD per share) $ 32.6
Share price (in USD per share) 32.6
Exercise price (in USD per share) $ 0.01
Expected option life | yr 10
Risk-free interest rate 3.85%
Expected dividend yield 0.00%
Expected probability of a liquidation event 0.00%
Bottom  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Expected volatility 62.60%
Top of range  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Expected volatility 62.88%